Information Provided By:
Fly News Breaks for April 5, 2018
ABT, QDEL
Apr 5, 2018 | 07:46 EDT
Canaccord analyst Mark Massaro raised his price target on Quidel (QDEL) to $64 from $55 following its analyst day. The analyst calls Quidel the largest remaining pure play human point of care diagnostics company remaining after Abbott (ABT) bought Alere. He believes it makes Quidel a buyout candidate and noted its execution has been better than almost anyone could have expected. Massaro reiterated his Buy rating on Quidel shares.
News For QDEL;ABT From the Last 2 Days
There are no results for your query QDEL;ABT